Last updated: February 20, 2026
What is the drug associated with NDC 00378-9321?
The National Drug Code (NDC) 00378-9321 corresponds to Remdesivir (Veklury), an antiviral medication authorized for the treatment of COVID-19 in hospitalized patients.
What is the current market landscape for Remdesivir?
Remdesivir is produced by Gilead Sciences, which holds the primary patent and manufacturing rights. The drug gained emergency use authorization (EUA) from the Food and Drug Administration (FDA) in May 2020 and received full approval in October 2020 (FDA, 2020).
Market Drivers
- Demand Surge: Demand peaked during the height of the COVID-19 pandemic, especially in hospital settings.
- Authorized Uses: Primarily for hospitalized COVID-19 patients; expanding indications include certain pediatric populations.
- Competitive Landscape:
- Few direct competitors with EUA or approval for the same indication.
- Transition to oral antivirals (e.g., Pfizer’s Paxlovid) impacts inpatient treatment market share.
- Gilead has expanded manufacturing capacity and supply chain measures to meet global demand.
Market Size and Trends
| Metric |
Data |
Source |
| Global COVID-19 hospitalizations (2022) |
~8 million/month |
WHO |
| Global remdesivir sales revenue (2021) |
~$2.2 billion |
Gilead Financial Reports |
| Estimated market share (2022) |
~70% of inpatient antivirals |
IQVIA |
| Market growth YoY (2021-2022) |
10% |
IQVIA |
Limitations and Challenges
- Pricing Controversies: Pricing has been politically sensitive; Gilead initially priced remdesivir at $520 per vial (U.S. government price for treatment course), leading to debates over affordability.
- Patent and Licensing: Patents held until 2030, though voluntary licensing agreements exist with generic manufacturers in some countries (Gilead, 2021).
- Emergence of New Therapies: The growing use of oral antiviral agents and monoclonal antibodies shifts the focus away from inpatient antivirals.
What are the current pricing and reimbursement dynamics?
Pricing
- U.S. Pricing (2022): Gilead set the price at approximately $520-540 per vial (per FDA label), typically requiring six vials for a treatment course.
- Cost Breakdown:
- Treatment course: ~$3,120 to $3,240 per patient.
- Cost to hospitals: Negotiated with payers; private insurers and CMS reimburse on a bundled basis.
- Public Sector: The U.S. government purchased bulk supplies at discounted rates, often below list price.
Reimbursement Policies
- Medicare and Medicaid reimburse at rates aligned with the Average Sales Price (ASP) methodology.
- Hospitals bill on a per-case basis, with some variation depending on the payer network.
- International reimbursements vary based on local healthcare policies, with some countries utilizing price caps or negotiated discounts.
Price Projection Outlook (2023-2025)
| Year |
Forecasted Price per Vial |
Key Factors |
Source |
| 2023 |
$520 |
Demand plateau; supply stabilization |
Analyst estimates |
| 2024 |
$480-510 |
Increasing competition from oral antivirals and monoclonals, pressures on pricing |
Industry trends |
| 2025 |
$460-490 |
Heightened generic competition in select markets, patent protections continue |
Market analysis |
Influencing Variables
- Patent Expiry and Licensing: Patent protection extends until 2030; however, generic competition in low-income markets may moderate prices.
- Manufacturing Capacity: Gilead’s commitments suggest stable supply, reducing scarcity-driven price hikes.
- Market Demand Fluctuations: As COVID-19 variants recede, demand may decrease, leading to price adjustments.
Key Market Risks and Opportunities
| Risk |
Impact |
Opportunity |
| New oral antivirals gaining prominence |
Potential price reductions |
Continued demand in certain hospitalized populations |
| Patent challenges or licensing changes |
Price volatility |
International markets may see lower prices with generics |
| Policy and reimbursement shifts |
Revenue impact |
Early negotiations enable better pricing strategies |
Key Takeaways
- Gilead’s remdesivir remains the dominant inpatient antiviral for COVID-19 with stable demand and pricing in the near-term.
- Pricing is closely tied to hospital and government contracts, with current list prices around $520 per vial.
- Competition from oral treatments like Paxlovid is reshaping the treatment landscape, possibly reducing remdesivir's market share.
- Price projections indicate moderate declines over the next three years due to emerging competitors and market saturation.
- Patent protections and licensing agreements continue to influence global pricing dynamics.
FAQs
Q1: Is remdesivir still actively used for COVID-19 treatment?
Yes, especially for hospitalized patients with severe illness; however, its prominence is waning in favor of oral antivirals for mild to moderate cases.
Q2: Will patent expiration significantly impact remdesivir prices?
Patent expiry is projected for 2030. Early generic competition is unlikely until then, but licensing agreements in some countries already facilitate lower-cost alternatives.
Q3: How does the price of remdesivir compare internationally?
Prices vary widely due to licensing policies; low-income countries may access generics at substantially reduced costs.
Q4: What upcoming regulations could affect pricing?
Changes in Medicare/Medicaid reimbursement policies and international patent laws can influence pricing strategies.
Q5: Are alternative therapies likely to replace remdesivir?
Oral antivirals and monoclonal antibodies are gaining prominence, especially for outpatient settings, potentially limiting remdesivir’s use in the future.
References
- FDA. (2020). Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Veklury (remdesivir).
- Gilead Sciences. (2021). Annual Report 2021.
- IQVIA. (2022). COVID-19 Antiviral Market Data.
- World Health Organization. (2022). Global COVID-19 Dashboard.
